Vendor Intelligence Report: Wuhan Wansheng Biotechnology

Executive summary

Wuhan Wansheng Biotechnology is not best read as a simple safe-or-scam file. The report separates a real China-based vendor from an active copycat ecosystem around it: observed WWB domains sit apart from lookalike and non-delivery domains, including wuhanwanshengbio.com, and one fraud cluster also points at a separate impersonation of another peptide vendor.

Across 221 Finnrick lab tests, WWB’s overall pass rate is 70%: 154 pass and 67 fail. The catalog is uneven rather than uniformly bad. Tirzepatide and retatrutide form the more defensible end of the tested set, while tesamorelin and CJC-1295 are weak enough that the buyer guidance changes from verify carefully to avoid absent exact-batch testing; ratings also compress under stricter grading.

The identity record is similarly mixed. Chinese business-search sources partially corroborate the corporate name, but full registry details remain paywalled and no Western legal entity was found. DNS records and forum evidence show a Hepius Pharma-to-WWB operating trail, while a removed Trustpilot profile, unverifiable review-count claims, and forum-documented missing-item disputes complicate the reputation picture.

For GLP-1 buyers, the product-quality signal is only one part of the decision. The report places WWB against FDA Import Alert 66-80, CBP’s China-origin peptide seizure activity, claimed USA warehouse options, crypto/wire payment friction, and the practical problem of verifying Cavan-linked Telegram and WhatsApp channels before irreversible payment.

Inside the full report:

• Per-product pass/fail rates, cumulative rating trajectories, and methodology-divergence charts for all 9 tested products
• Domain/IP/registrar map separating observed WWB domains from the wuhanwanshengbio.com, wuhanwansheng.net, and ggpeps.net risk cluster
• Hepius Pharma rebrand trail using DNS records, Wayback timing, and MESO-Rx product-presentation evidence
• Trustpilot removal capture, Janoshik and PeptideMeter signal analysis, and COA-verification caveats
• Contact-channel review for Cavan, Daisy, Garry, Telegram, WhatsApp, and payment-rail authentication
• FDA Import Alert 66-80, CBP Cincinnati seizure context, Green List review, and no-warning-letter negative finding

Risk assessment

• Copycat and brand-confusion concern — high: wuhanwanshengbio.com and wuhanwansheng.net are fraud or non-delivery concerns; wuhanwanshengbio.com shares IP and registrar patterns with ggpeps.net, and robust anti-counterfeit signals were not found.
• Review and order-resolution conduct concern — high: Trustpilot removed the WWB profile, and forum records describe missing-item disputes resolved as store credit rather than immediate reshipment or refund.
• Fail-heavy product quality concern — Tesamorelin, CJC-1295, TB-500 and BPC-157 — high: Tesamorelin 25.32%, CJC-1295 26.78%, TB-500 36.51% and BPC-157 45.08% are weak enough to avoid absent exact-batch independent testing.
• Borderline product quality concern — Cagrilintide — medium: Cagrilintide’s 58.2% Finnrick record is materially weaker than WWB’s stronger GHK-Cu, tirzepatide and retatrutide categories.
• Import-seizure and regulatory concern — high: GLP-1 purchases such as tirzepatide and retatrutide face FDA Import Alert 66-80 exposure; WWB was not found on the Green List, and CBP reported 5,000+ China-origin peptide seizures.
• Corporate transparency and rebrand concern — medium: The Chinese entity is partially corroborated, but full registry details were paywalled, no Western legal entity was found, and records indicate continuity from Hepius Pharma.